Primary breast lymphoma in the right breast during treatment for left breast cancer by Nagata, Shigeyuki et al.
BioMed  Central
Page 1 of 5
(page number not for citation purposes)
World Journal of Surgical Oncology
Open Access Case report
Primary breast lymphoma in the right breast during treatment for 
left breast cancer
Shigeyuki Nagata*, Ataru Nishimura, Yukio Iwashita, Tadahiko Kinoshita, 
Kengo Fukuzawa, Hideya Tashiro and Kenzo Wakasugi
Address: Department of Surgery, Oita Red Cross Hospital, Oita, Japan
Email: Shigeyuki Nagata* - ngkkd637@yahoo.co.jp; Ataru Nishimura - atarunishimura@yahoo.co.jp; Yukio Iwashita - geka4@oita-rc-hp.jp; 
Tadahiko Kinoshita - geka3@oita-rc-hp.jp; Kengo Fukuzawa - geka2@oita-rc-hp.jp; Hideya Tashiro - h-tashiro@oitakenbyo.jp; 
Kenzo Wakasugi - soumuka1@oita-rc-hp.jp
* Corresponding author    
Abstract
Background: Primary breast lymphoma is a rare condition, and distinguishing it from breast
cancer is important because their treatments differ radically. Moreover, a recent report showed
that mastectomy offered no benefit in the treatment of primary breast lymphoma.
Case presentation: A 59-year-old woman was treated with adjuvant chemotherapy and local
radiation after surgery for left breast cancer. She presented with a rapidly growing mass in the right
breast at 20 months after surgery. Mammography and computed tomography revealed a massive
tumour. She was diagnosed with primary breast lymphoma by aspiration cytology, and surgery was
performed. Histopathological and immunohistochemical findings confirmed a diffuse large B-cell
type primary breast lymphoma.
Conclusion: In this case, the lymphoma exhibited rapid growth despite chemotherapy for a
malignancy in the contralateral breast. The patient had developed bronchiolitis obliterans
organizing pneumonia due to radiation. Therefore, surgical treatment of the lymphoma was
selected.
Background
Primary breast lymphoma (PBL) is a rare condition, and it
represents less than 0.7% of all malignant breast tumours.
It affects less than 1% of patients with non-Hodgkin lym-
phoma (NHL) and constitutes only 2% of all extranodal
NHLs [1-9]. Further, few reports are available on PBL, and
the sample size used in all clinical studies is small.
The clinical presentation and radiological features of this
condition do not differ from those of breast cancer. PBL is
mostly observed in females. The most common presenta-
tion of either malignancy is a painless enlarging breast
mass [1]. On a mammogram, these lymphomas may lack
the irregular borders of infiltrating carcinomas, and more
than half the tumors exhibit no calcification [1,2]. Despite
the clinical and radiographic similarities between the 2
tumor types, their treatments differ radically. Hence, it is
important to accurately distinguish lymphomas from
other breast malignancies in order to appropriately triage
patients for treatment. Fine-needle aspiration cytology is
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one of the most useful methods for the diagnosis of lym-
phoproliferative disorders, and its overall sensitivity is
approximately 90% [2,3,7].
PBL treatment varies widely, and surgical therapy options
range from biopsy to modified radical mastectomy. More
recently chemotherapy using various agents has been rec-
ognized as the preferred treatment. Radiotherapy may be
used as an adjuvant therapy or as a primary local therapy
[9,10]. Treatment options may also include immuno-
therapy or radioimmunotherapy. A very recent study
reported that mastectomy offered no benefit in the treat-
ment of PBL, and treatment that included chemotherapy
and/or radiation therapy provided benefits with regard to
both the survival and recurrence rates [11].
With such paucity of data, it is more difficult to derive
valid conclusions regarding the epidemiology, appropri-
ate management, and prognosis of PBL as compared to
lymphomas at other sites. Many reports conclude that the
breast is an unfavourable primary site and that this malig-
nancy exhibits a significantly poorer prognosis than other
localized lymphomas [4,8]. However, no clear consensus
for therapy has emerged. Therefore, accumulation of data
in the form of case reports, clinical studies, etc., is impor-
tant.
In this study, we report the case of a female patient who
underwent treatment for breast cancer and later presented
with a rapidly growing PBL in the contralateral breast.
This is an extremely unusual case because two considera-
bly different diseases were manifested in single patient.
Selecting the best treatment option from among chemo-
therapy, radiation, surgical therapy, etc was difficult. This
report describes and discusses the physical findings, diag-
nosis, and treatment of this condition.
Case presentation
A 58-year-old woman underwent total mastectomy and
dissection of the axillary lymph nodes (Auchincloss-Mad-
den method) as treatment for left breast cancer in April
2004. Based on histological findings, she was diagnosed
with stage IIB invasive ductal carcinoma (T2 N1 M0), and
immunohistochemical findings revealed that the tumour
cells were strongly positive for HER-2, very weakly posi-
tive for the oestrogen receptor, and negative for the pro-
gesterone receptor. The patient was sequentially treated
with adjuvant chemotherapy (5 cycles of pirarubicin and
cyclophosphamide [AC therapy; total dose of pirarubicin,
250 mg]). After AC therapy, she was administered tegafur/
uracil (UFT; 400 mg/day). In March 2005, she com-
plained of reddish skin eruptions over the left chest.
Biopsy revealed a diagnosis of cancer recurrence, and she
was treated with local radiation (total dose, 60 Gy). The
areas of reddish skin eruptions apparently decreased, and
chemotherapy (90 mg/body paclitaxel every week) was
administered after radiation therapy. Later, the patient
presented with high-grade fever, and a diffuse infiltrative
shadow was seen on a chest X-ray image in October 2005.
Based on her past history and chest computed tomogra-
phy (CT) findings, she was diagnosed with bronchiolitis
obliterans organizing pneumonia (BOOP) due to radia-
tion. She was consequently treated with oral prednisolone
(starting dose, 40 mg/day; maintenance dose, 15 mg/day)
for 2 months. Her symptoms and imaging findings indi-
cated improvement. In November 2005, a mass (diame-
ter, <5 cm) in the right breast was recognized without any
other symptoms. After a month, the huge mass in the right
breast could be palpated; it was >10 cm in diameter, dis-
tended, and slightly tender. The laboratory blood levels of
almost all test items were within the normal range, except
for the level of lactate dehydrogenase (LDH) that was 873
IU/L (normal range, 200–400 IU/L). The tumour marker
levels were as follows: carcinoembryonic antigen (CEA),
1.6 ng/mL (normal range, <5.0 ng/mL); carbohydrate
antigen 15-3 (CA15-3), 8.0 U/mL (normal range, <31 U/
mL); and soluble interleukin-2 receptor (sIL-2R), 1390 U/
mL (normal range, 220–530 U/mL). A mammogram
revealed a large lobulated tumour lodged in the right
mammary gland with no microcalcifications. Ultrasound
(US) demonstrated that the lesion comprised well-
defined hypoechoic nodules with low-level internal ech-
oes and that it enhanced through transmission; these find-
ings were consistent with those of a malignant
lymphoma. Ga-67 scintigraphy showed intense accumu-
lation in the tumour. These findings were supported by
those of fine-needle aspiration cytology that revealed large
dysplastic lymphocytes with irregular nuclei and numer-
ous mitotic figures. Chest CT revealed multiple nodules in
the right breast that were uniformly enhanced and had a
density identical to the soft tissue density; no apparent
axillary lymph node swelling was noted. This tumour
showed rapid growth, and its doubling time was calcu-
lated to be 8 days (Figure 1). Because this patient had
undergone chemotherapy for breast cancer and had
BOOP due to radiation, we considered it difficult for her
to undergo additional chemotherapy or radiation therapy
for the breast lymphoma; the patient finally opted for sur-
gical therapy. Total mastectomy and axillary dissection
(Auchincloss-Madden method) were performed in Janu-
ary 2006 (Figure 2). Based on the morphologic features of
the tumour and immunophenotyping, the PBL was diag-
nosed to be of the diffuse large B-cell type (World Health
Organization classification). The tumour cells were nega-
tive for CD3 and were diffusely positive on staining for the
leukocyte common antigen L26, CD10, and bcl-2 (Figure
3). The level I lymph nodes were infiltrated by lymphoma
cells. The patient received 8 cycles of chemotherapy (ritux-
imab, 600 mg/body and CHOP [cyclophosphamide, 700
mg/body; doxorubicin, 45 mg/body; vincristine, 3 mg/World Journal of Surgical Oncology 2007, 5:134 http://www.wjso.com/content/5/1/134
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body; and methylprednisolone, 250 mg/body] every 4
weeks). She was clinically disease free at 1 year after sur-
gery.
Discussion
The risk of secondary malignancies among female breast
cancer patients has been studied for decades. Yu G et al.,
reported that the risk ratio of NHL assessed by comparing
female breast cancer patients to the general population
was 2.1 in the young group (20–49 years) [12].
The most common type of PBL is the diffuse large B-cell
type, and its characteristics are consistent with those
observed in the present case [1,2,7]. For PBL diagnosis,
most studies use the criteria described by Wiseman and
Liao: (1) A pathological specimen that demonstrates a
close association between the lymphomatous infiltrate
and the breast tissue is available in sufficient amount. (2)
There is no evidence of concurrent widespread disease or
preceding extramammary lymphoma. (3) The breast is the
clinical site of presentation, but ipsilateral lymph node
involvement is considered acceptable if both lesions
develop simultaneously [3].
In middle-aged females, PBLs are most commonly
detected as a solitary palpable mass. Men are rarely
affected by this disease. Many studies report that PBL is
more common in the right breast, especially the upper
outer quadrant, which is almost consistent with the find-
ings in this case [1,7].
PBLs are not usually detected by screening mammogra-
phy. However, mammograms obtained after the identifi-
cation of a palpable mass demonstrate a parenchymal
abnormality in most cases. There is no specific mammo-
graphic characteristic that can be used for lymphoma
diagnosis. The most common mammographic findings
include a solitary well-defined mass that may have an
irregular border, which is consistent with the finding in
the present case. PBLs rarely demonstrate calcification or
a spiculated appearance on mammography [1,2,5,7].
US evaluation of PBL usually demonstrates a hypoechoic
lesion with well-defined borders that lack significant pos-
terior enhancement or acoustic shadowing that may
falsely indicate a benign cyst; these findings are similar to
those in this case [1,2,5]. However, they are not a consist-
ent feature of PBL because other reports have mentioned
many variations [13].
Macroscopic findings of the tumour Figure 2
Macroscopic findings of the tumour. The resected 
tumour appeared aggregated with some nodules.
Chest CT images Figure 1
Chest CT images. A) CT was performed on November 22, 2005. B) CT was performed on December 21, 2005. The 
tumour apparently enlarged during a month. The doubling time was calculated at the same area (arrow) of the tumour.World Journal of Surgical Oncology 2007, 5:134 http://www.wjso.com/content/5/1/134
Page 4 of 5
(page number not for citation purposes)
Thus far, no clear clinical or radiological features that can
distinguish PBLs from infiltrating breast carcinomas have
been found. Adequate tissue biopsy based on histopatho-
logical evaluation and immunophenotyping continues to
be the key in evaluating these patients [1-3,6,7].
There are various treatment options for PBL: surgery, radi-
ation, and chemotherapy have been used alone or as com-
bination therapy. Chemotherapy with or without
adjuvant radiotherapy is the most common therapeutic
approach [1-3,9,10]. The role of surgery in PBL treatment
is often restricted to obtaining adequate tissue for accurate
lymphoma diagnosis and classification, and PBL treat-
ment is similar to that for lymphomas at other sites [1,3].
A recent paper showed that treatment by mastectomy
offered no survival benefit or protection from recurrence
[11]. It reported that treatment including radiation ther-
apy in node-negative patients and treatment including
chemotherapy in node-positive patients exhibited benefit
with regard to both survival and recurrence rates.
The survival rates of patients with PBL are comparable to
those with lymphomas in general and are favorable when
compared to the survival rates of those with breast carci-
noma. Prognosis depends on the histological tumor grade
[1,4,8]. The international Prognostic Index considers age,
LDH levels, performance status, Ann Arbor staging, and
the presence of extranodal tumor in predicting the 5-year
survival [2,14]. The most common site of relapse is report-
edly the central nervous system [8-10].
This patient showed an unusual clinical course: PBL was
discovered 20 months after surgery for a malignancy in
the opposite breast. The tumour was recognized after the
patient was treated with adjuvant AC chemotherapy and
radiation therapy for local recurrence of breast cancer and
while she was receiving oral prednisolone for BOOP. The
patient was administered 3 of the 4 drugs used in CHOP
chemotherapy for malignant lymphoma; despite this, PBL
developed. Finally, due to the rapid growth of the tumour,
resection was performed instead of chemotherapy or radi-
ation therapy.
Conclusion
It is difficult to select the treatment modality for PBL, but
we considered surgical therapy to be better in this very
special case. The patient was pronounced disease free at 1
year after surgery.
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